Fiasp

GPTKB entity

Statements (60)

Predicate	Object
gptkbp:instance_of	gptkb:diabetes
gptkbp:approves	gptkb:2017
gptkbp:brand	gptkb:Fiasp
gptkbp:clinical_trial	conducted for safety conducted for efficacy
gptkbp:clinical_use	type 2 diabetes type 1 diabetes
gptkbp:contraindication	severe hypoglycemia diabetic ketoacidosis hypersensitivity to insulin aspart
gptkbp:developed_by	gptkb:Novo_Nordisk
gptkbp:dosage_form	subcutaneous injection
gptkbp:duration	up to 5 hours
gptkbp:financial_support	available for users
gptkbp:form	gptkb:PEN_International vial
gptkbp:formulation	gptkb:insulin_aspart
gptkbp:healthcare	gptkb:Software_Solutions
https://www.w3.org/2000/01/rdf-schema#label	Fiasp
gptkbp:indication	mealtime insulin
gptkbp:ingredients	gptkb:insulin_aspart
gptkbp:interacts_with	gptkb:beer beta-blockers other antidiabetic medications
gptkbp:marketed_as	multiple countries Novo Nordisk brand
gptkbp:mechanism_of_action	mimics natural insulin
gptkbp:packaging	vials pre-filled pens
gptkbp:patient_education	proper injection technique recognize hypoglycemia symptoms monitor blood glucose dietary considerations exercise impact on insulin
gptkbp:patient_population	gptkb:children adults
gptkbp:pharmacokinetics	lowers blood glucose levels rapid absorption peak effect at 1-3 hours
gptkbp:premiered_on	within 20 minutes
gptkbp:provides_guidance_on	recommended for mealtime use used in insulin pumps
gptkbp:regulatory_compliance	gptkb:FDA gptkb:EMA
gptkbp:research	long-term safety studies ongoing efficacy studies comparative studies with other insulins
gptkbp:route_of_administration	subcutaneous injection
gptkbp:shelf_life	28 days after opening up to 36 months unopened
gptkbp:side_effect	nausea allergic reactions weight gain injection site reactions hypoglycemia reported in clinical trials
gptkbp:storage	refrigerated
gptkbp:used_for	diabetes management
gptkbp:bfsParent	gptkb:Novolog
gptkbp:bfsLayer	5